Rafid Mustafa, M.D.

Open

• An Open-Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, Efficacy, And Safety Of A Single Dose Of Tanruprubart (Also Commonly Known As ANX005) In Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study) Rochester, Minn. The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.